ENTRY       D04603                      Drug
NAME        Ipilimumab (USAN/INN);
            Ipilimumab (genetical recombination) (JAN);
            Yervoy (TN)
PRODUCT     YERVOY (E.R. Squibb & Sons)
FORMULA     C6472H9972N1732O2004S40
EXACT_MASS  145300.0471
MOL_WEIGHT  145389.4301
SEQUENCE    (Heavy chain)
            QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYTMHWVRQA PGKGLEWVTF ISYDGNNKYY
            ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAIYYCARTG WLGPFDYWGQ GTLVTVSSAS
            TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
            YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
            YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
            GNVFSCSVMH EALHNHYTQK SLSLSPGK
            (Light chain)
            EIVLTQSPGT LSLSPGERAT LSCRASQSVG SSYLAWYQQK PGQAPRLLIY GAFSRATGIP
            DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG QGTKVEIKRT VAAPSVFIFP
            PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
            TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
            (Disulfide bridge: H22-H96, H145-H201, H221-L215, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'215, H'262-H'322, H'368-H'426, L23-L89, L135-L195, L'23-L'89, L'135-L'195)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FX04
            Product: D04603<JP/US>
EFFICACY    Antineoplastic, Immune checkpoint inhibitor, Anti-CTLA4 antibody
  DISEASE   Melanoma [DS:H00038]
            Renal cell carcinoma [DS:H00021]
            Colorectal cancer (MSI-H or dMMR) [DS:H00021]
            Hepatocellular carcinoma [DS:H00048]
  TYPE      Monoclonal antibody
TARGET      CTLA4 (CD152) [HSA:1493] [KO:K06538]
  PATHWAY   hsa04660(1493)  T cell receptor signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX04 Ipilimumab
                  D04603  Ipilimumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Ipilimumab
                D04603  Ipilimumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D04603  Ipilimumab (USAN/INN); Ipilimumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D04603  Ipilimumab
            Drug classes [BR:br08332]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D04603  Ipilimumab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                CTLA4 (CD152)
                 D04603  Ipilimumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D04603
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D04603
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D04603
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D04603
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D04603
DBLINKS     CAS: 477202-00-9
            PubChem: 47206447
///
